Hereditary Angioedema
📧 Sign up to get email alerts when something new happens for Hereditary Angioedema.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-17Clinical Trial Results: Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II [Phase 2]
A Phase 2 dose-ranging study evaluating oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (Types …
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II [Phase 3]
Phase 3 open-label trial assessing safety, pharmacokinetics, and efficacy of sebretalstat (KVD900) in pediatric patients with hereditary ang…
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial [Phase 3]
Phase 3 PK subtrial in adolescents with hereditary angioedema participating in the KVD900-302 trial has completed.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) [Phase 3]
Open-label extension trial assessing long-term safety of KVD900 (sebentralstat) for on-demand treatment of angioedema attacks in adolescents…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Results: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]
Phase 3 results for garadacimab (CSL312) in long-term prophylaxis of hereditary angioedema indicate safety and efficacy outcomes from comple…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Results: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema [Phase 3]
Phase 3 trial results for CSL312_3003 safety and pharmacokinetics in children aged 2 to 11 with hereditary angioedema (HAE) have been comple…
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]
Phase 3 trial update on garadacimab (CSL312) for prophylaxis of hereditary angioedema shows completed study with posted results.
-
CLINICAL_TRIALS trial_result · 2026-06-02Clinical Trial Update: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema [Phase 3]
Phase 3 safety and pharmacokinetic trial of CSL312_3003 in children aged 2 to 11 with hereditary angioedema; study completed with results po…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of ADX-324 in healthy volunteers and patient…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia
The update describes a study of lanadelumab in teenagers and adults with hereditary angioedema in the Kingdom of Saudi Arabia, which is curr…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Donidalorsen Treatment in Children With Hereditary Angioedema [Phase 3]
Phase 3 trial evaluating donidalorsen for hereditary angioedema in children is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Takeda-sponsored clinical study evaluating lanadelumab for hereditary angioedema (HAE) in Poland has completed.
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema [Phase 2, Phase 3]
Extension study of oral PHA-022121 for acute treatment of angioedema attacks in hereditary angioedema. The trial is in Phase 2/Phase 3 and i…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
A clinical trial update shows a South Korea study of lanadelumab (Takhzyro) for hereditary angioedema in teenagers and adults is NOT_YET_REC…
-
CLINICAL_TRIALS trial_result · 2026-03-02Clinical Trial Update: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients [Phase 1, Phase 2]
Clinical trial update reports on safety, tolerability, and pharmacokinetics/pharmacodynamics of ADX-324 in healthy volunteers and hereditary…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Berotralstat Treatment in Children With Hereditary Angioedema [Phase 3]
Phase 3 trial update reporting results for berotralstat in pediatric hereditary angioedema; the study is active but not recruiting, with res…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) [Phase 3]
Open-label extension study evaluating the long-term safety of KVD900 (Sebetralstat) for on-demand treatment of angioedema attacks in adolesc…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE [Phase 3]
Phase 3 clinical trial update evaluating an extended-release oral deucrictibant tablet for prophylaxis of angioedema attacks in adolescents …
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema [NA]
A completed clinical trial conducted at University Hospital, Rouen, investigating the role of monocytic B1 and B2 receptors in inflammation …
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat
This clinical trial update reports on the use of Sebetralstat for treating angioedema attacks in pediatric patients aged 2-11 with hereditar…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]
Phase 3 study evaluating long-term safety and efficacy of garadacimab (CSL312) as prophylaxis for hereditary angioedema completed.
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema [Phase 3]
A Phase 3 safety and pharmacokinetic study of CSL312_3003 in children aged 2 to 11 with hereditary angioedema has completed.
-
CLINICAL_TRIALS trial_result · 2026-01-23Clinical Trial Update: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II [Phase 3]
Open-label Phase 3 pediatric trial evaluating safety, pharmacokinetics, and efficacy of Sebetralstat (KVD900) in children aged 2-11 with her…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
This update indicates the completion of a clinical trial evaluating lanadelumab (Takhzyro) and icatibant (Firazyr) for hereditary angioedema…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
A completed observational study in the United States evaluating icatibant for treating attacks in patients with hereditary angioedema types …